News
Public · Published
Amneal Pharmaceuticals, Inc. (AMRX) Raises 2026 Guidance After Revenue Grows 10%
Amneal Pharmaceuticals reported third-quarter 2026 revenue of $863 million, up 10% from $785 million a year earlier, and adjusted EBITDA, a measure of operating performance, rose 30% to $207 million. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted earnings per share.
Published:
Updated:
What happened
Amneal Pharmaceuticals reported third-quarter 2026 revenue of $863 million, up 10% from $785 million a year earlier, and adjusted EBITDA, a measure of operating performance, rose 30% to $207 million. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted earnings per share.
Confirmed
Global impact / market context
Revenue and adjusted profit growth point to stronger operating performance, but the reported net loss shows that adjusted results do not capture all costs. Higher inventory needs also limit the cash expected from operations, potentially constraining funds available for other company needs.
Analyst inference
The article describes growth across Affordable Medicines and Specialty, while AvKARE revenue declined 17% against a prior-year product launch. This uneven performance, together with acquisition and integration costs and higher taxes, means headline growth does not describe every business or measure of earnings.
Analyst inference
What to watch
- Look for Amneal to publish the revised full-year revenue, adjusted EBITDA and adjusted earnings-per-share targets; the article says guidance increased but gives no new target figures. Confirmed
- Track whether inventory in growth areas continues to raise working-capital needs, meaning cash tied up in daily operations, and reduces operating cash flow against the updated outlook. Analyst inference
- Check whether AvKARE's 17% decline persists and whether growth in Affordable Medicines and Specialty offsets it, since the article gives no future segment forecasts. Analyst inference